Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients

20031,195 citationsJournal Articlebronze Open Access

Authors

Howard J. Eisen · Temple University

E. Murat Tuzcu · Cleveland Clinic

Richard Dorent · Sorbonne Université

Jon Kobashigawa · University of California, Los Angeles

Donna Mancini · NewYork–Presbyterian Hospital

Hannah A. Valantine-von Kaeppler

Randall C. Starling · Cleveland Clinic

Abstract

Everolimus was more efficacious than azathioprine in reducing the severity and incidence of cardiac-allograft vasculopathy, suggesting that everolimus therapy may alleviate this serious problem.

Topics & Keywords

Transplantation: Methods and Outcomes Renal Transplantation Outcomes and Treatments Polyomavirus and related diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 349, Issue 9, pp. 847-858

DOI: 10.1056/nejmoa022171

Field-Weighted Citation Impact: 83.60